Journal de pharmacocinétique et thérapeutique expérimentale

Accès libre

Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

Phenolic acid tethered co-drugs of isoniazid: Synthesis, pharmacokinetics and investigation of antimycobacterial and hepatoprotective potential

Neha V. Bhilare

According to WHO statistics of 2018, there were an estimated 1.2 million TB deaths among HIV-negative people. Isoniazid is being used for more than 60 years in the treatment of this deadly disease, but emergence of resistance towards this drug and metabolic and morphological aberrations in the liver have raised serious concerns regarding its continued use in future.

To overcome these hazardous effects, a novel hepatoprotective and antimycobacterial prodrug strategy was developed by combining INH with phenolic acids (gallic acid, syringic acid &vanillic acid) as antioxidant promoeities for probable synergistic effect.

Prodrugs synthesized by Schotten Baumann reaction were characterized by spectral analysis and in vitro and in vivo release studies were carried out using HPLC. Their hepatoprotective potential was evaluated in male Wistar rats by performing the liver function tests, oxidative stress markers and histopathology studies. The antimycobacterial efficacy of prodrugs was examined in terms of its ability to decrease the lung bacillary load in Balb/c mice infected intravenously with Mycobacterium tuberculosis.